Christopher Self
26Patents
7h-index
48Co-inventors
69Inventor score
Filing activity: Oct 10, 1986 → Mar 8, 2016
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6548477B1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | Emerging Cross-Sectional Technologies | 87 | Expired |
| US7084108B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | Chemistry; Metallurgy | 54 | Expired |
| US7268111B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | Chemistry; Metallurgy | 52 | Expired |
| US7432342B2 | Kinase anchor protein muteins, peptides thereof and related documents | Human Necessities | 29 | Expired |
| US7037890B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | Emerging Cross-Sectional Technologies | 25 | Expired |
| US6919307B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | Emerging Cross-Sectional Technologies | 13 | Expired |
| US7105482B2 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | Emerging Cross-Sectional Technologies | 8 | Expired |
| US4774253A | Oxazole and isoxazole derivatives having anti-arthritic activity | Chemistry; Metallurgy | 7 | Expired |
| US8222215B2 | Methods for the use of inhibitors of antigen presentation by MHC class II molecules | Human Necessities | 7 | Active |
| US7439231B2 | Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof | Human Necessities | 7 | Expired |
| US6610658B1 | Modulators of &mgr;-amyloid peptide aggregation | Human Necessities | 7 | Expired |
| US8598312B2 | Inhibitors of antigen presentation by MHC class II molecules | Human Necessities | 6 | Active |
| US7348307B2 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | Emerging Cross-Sectional Technologies | 6 | Expired |
| US7157420B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | Emerging Cross-Sectional Technologies | 6 | Expired |
| US9592221B2 | Antibacterial agents: aryl myxopyronin derivatives | Emerging Cross-Sectional Technologies | 5 | Active |
| US7947645B2 | APO E analogs and methods for their use | Emerging Cross-Sectional Technologies | 5 | Active |
| US9315495B2 | Antibacterial agents: aryl myxopyronin derivatives | Emerging Cross-Sectional Technologies | 4 | Active |
| US7405194B2 | Therapeutic agents and methods of use thereof for the treatment of melanoma | Chemistry; Metallurgy | 2 | Expired |
| US7981885B2 | Compositions for treatment of diseases related to activated lymphocytes | Chemistry; Metallurgy | 2 | Active |
| US5114960A | Substituted isoxazole derivatives | Chemistry; Metallurgy | 1 | Expired |
| US9278089B2 | Method of treating HCV infection with a small molecule CHK2 inhibitor | Chemistry; Metallurgy | 0 | Active |
| US8765802B2 | Kinase inhibitors, compositions thereof, and methods of use therewith | Chemistry; Metallurgy | 0 | Active |
| US5994569A | Dihomo-seco-cholestanes | Human Necessities | 0 | Expired |
| US7923445B2 | Methods for treatment of diseases related to activated lymphocytes | Chemistry; Metallurgy | 0 | Active |
| US7803774B2 | Modulators of β-amyloid peptide aggregation | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.